Corneal astigmatism and HOAs affect IOL performance

Article

Uncorrected corneal astigmatism and higher-order aberrations (HOAs) in pseudophakic eyes significantly affects through-focus performance of presbyopia-correcting IOLs.

Uncorrected corneal astigmatism and higher-order aberrations (HOAs) in pseudophakic eyes significantly affects through-focus performance of presbyopia-correcting IOLs.

Dr Len Zhelezynak and his team, Flaum Eye Institute, University of Rochester, Rochester, New York, USA, conducted an experimental study on the impact of corneal aberrations on the through-focus image quality of presbyopia-correcting IOLs using an adaptive optics IOL metrology system.

The device was used to induce corneal astigmatism and HOAs and the image-capturing system acquired through-focus images of a letter chart with 3.0 mm and 5.0 mm pupil diameters.

A single-optic accommodating IOL, an apodized diffractive multifocal IOL, a full-aperture diffractive multifocal IOL and a monofocal IOL were assessed. The correlation-coefficient image-quality metric was used to quantify image quality.

The single-optic accommodating IOL produced a better intermediate image quality, compared to the monofocal IOL. Corneal astigmatism reduced the through-focus quality and depth of focus with all IOLs, but the multifocal IOL had the more significant reduction in depth of focus.

The abstract is available in the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.